查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
胃酸分泌藥物市場 2022-2028
市場調查報告書
商品編碼
1215803

胃酸分泌藥物市場 2022-2028

Gastric Antisecretory Drug Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 | 商品交期: 2-3個工作天內

價格

在預測期內，全球胃酸抑製劑市場預計將以 3.8% 的複合年增長率增長。 世界主要國家因不健康生活方式的轉變，導致胃食管反流病（GERD）、胃酸過多、消化性潰瘍等疾病負擔日益加重，推動抗胃分泌藥需求急劇增加。 此外，專注於研發和市場擴張活動以將高度可靠的新配方引入市場的主要公司的存在也是市場增長的推動力。

全球酸抑製劑市場根據類型、應用和最終用戶進行細分。 按類型劃分，市場分為 H2 受體拮抗劑、胃質子泵抑製劑等。 胃質子泵抑製劑部分有望見證市場增長的潛在份額。 GERD 的日益流行和對新藥物輸送系統的日益接受是推動該領域增長的一些關鍵因素。 根據應用，市場分為消化不良、消化性潰瘍、胃食管反流等。 根據最終用戶，市場分為醫院、診所等。

按地區劃分，胃酸抑製劑市場分為北美、歐洲、亞太地區和世界其他地區。 由於對胃腸道疾病和疾病的認識提高以及醫療保健基礎設施的改善，預計北美和歐洲將佔據主要市場份額。 這些地區的生物製藥公司正在大力投資研發活動，大量產品處於臨床審批的不同階段，並有可能在預測期內實現商業化。 此外，由於患有胃病的老年人越來越多以及對聯合療法的偏好，對抑酸藥物的需求增加，預計亞太地區抑酸劑市場將增長最快。

內容

第 1 章報告概述

  • 當前行業分析和增長前景
  • 全球酸抑製劑行業的複蘇情景
  • 研究方法和工具
  • 市場細分
    • 按細分
    • 按地區

第 2 章市場概述和洞察

  • 調查範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 推薦
    • 總結

第三章競爭格局

  • 主要公司分析
    • 概覽
    • 財務分析
    • SWOT 分析
    • 近期趨勢
  • 關鍵策略分析

第四章市場細分

  • 全球酸抑製劑市場類型
    • H2 受體拮抗劑
    • 胃質子泵抑製劑
    • 其他
  • 按應用劃分的全球酸抑製劑市場
    • 消化不良
    • 消化性潰瘍
    • 胃食管反流病
    • 其他
  • 按最終用戶劃分的全球酸抑製劑市場
    • 醫院
    • 診所
    • 其他

第五章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 世界其他地方
    • 拉丁美洲
    • 中東和非洲

第六章公司簡介

  • ALTANA Group
  • AstraZeneca plc
  • Bayer AG
  • Cadila Pharmaceuticals
  • Cheplapharm Arzneimittel GmbH
  • Cipla Inc.
  • Eisai Co., Ltd
  • Luoxin Group
  • Pfizer, Inc.
  • Novartis International AG
  • SANIS Health Inc.
  • Sanofi-Aventis U.S. LLC
  • Shandong Luoxin Pharmaceutical Group Stock co., ltd
  • Takeda Pharmaceutical Co. Ltd.
Product Code: OMR2026859

Title:Global Gastric Antisecretory Drug Market Size, Share, and Trends Analysis Report, By Type (H2-receptor Antagonists, Gastric Proton Pump Inhibitors, and Others), By Application (Dyspepsia, Peptic Ulcer, Gastroesophageal Reflux, and Others), By End-User (Hospitals, Clinics, and Others), Forecast Period (2022 to 2028).

The global gastric antisecretory drug market is anticipated to grow at a CAGR of 3.8% during the forecast period. The rising burden of gastroesophageal reflux disease (GERD), gastroesophageal reflux, peptic ulcer, and other diseases in the major economies globally due to people's shift toward unhealthy lifestyles is the key factor surged the demand for gastric antisecretory drugs. The market growth is also driven by the presence of major market players who are focused on R&D and market expansion activities to bring new and reliable formulations to the market.

The global gastric antisecretory drug market is segmented based on type, application, and end-user. Based on type, the market is segmented into H2-receptor antagonists, gastric proton pump inhibitors, and others. The gastric proton pump inhibitors segment is likely to witness a potential share in the growth of the market. The increasing prevalence of GERD and the rising acceptance of novel drug delivery systems are some crucial factors that have boosted the segment growth. Based on application, the market is segmented into dyspepsia, peptic ulcer, gastroesophageal reflux, and others. Based on end-user, the market is segmented into hospitals, clinics, and others.

Geographically, the gastric antisecretory drug market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America and Europe are expected to hold a major share of the market owing to the surge in awareness about gastrointestinal disorders/diseases and improvement in health care infrastructure. Biopharmaceutical companies in these regions have made significant investments in R&D activities, and a large number of pipeline products are at different stages of clinical approval and are likely to commercialize during the forecast period. Besides, the gastric antisecretory drug market in the Asia-Pacific region is expected to be the fastest growing owing to the increasing geriatric population affected with gastric problems that have increased the demand for gastric antisecretory drugs and surging preference for combination therapies.

The major players in the global gastric antisecretory drug market include Pfizer Inc., Sanofi-Aventis US LLC, and Takeda Pharmaceutical Co. Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market.

Research Methodology

The market study of the global gastric antisecretory drug is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Gastric Antisecretory Drug Research and Analysis by Type
  • Global Gastric Antisecretory Drug Research and Analysis by Application
  • Global Gastric Antisecretory Drug Research and Analysis by End-User

The Report Covers:

  • Comprehensive research methodology of the global gastric antisecretory drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global gastric antisecretory drug market.
  • Insights about market determinants that are stimulating the global gastric antisecretory drug market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Recovery Scenario of Global Gastric Antisecretory Drug Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Gastric Antisecretory Drug Market by Type
    • 4.1.1. H2-receptor Antagonists
    • 4.1.2. Gastric Proton Pump Inhibitors
    • 4.1.3. Others
  • 4.2. Global Gastric Antisecretory Drug Market by Application
    • 4.2.1. Dyspepsia
    • 4.2.2. Peptic Ulcer
    • 4.2.3. Gastroesophageal Reflux
    • 4.2.4. Others
  • 4.3. Global Gastric Antisecretory Drug Market by End-User
    • 4.3.1. Hospital
    • 4.3.2. Clinic
    • 4.3.3. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World
    • 5.4.1. Latin America
    • 5.4.2. Middle East & Africa

6. Company Profiles

  • 6.1. ALTANA Group
  • 6.2. AstraZeneca plc
  • 6.3. Bayer AG
  • 6.4. Cadila Pharmaceuticals
  • 6.5. Cheplapharm Arzneimittel GmbH
  • 6.6. Cipla Inc.
  • 6.7. Eisai Co., Ltd
  • 6.8. Luoxin Group
  • 6.9. Pfizer, Inc.
  • 6.10. Novartis International AG
  • 6.11. SANIS Health Inc.
  • 6.12. Sanofi-Aventis U.S. LLC
  • 6.13. Shandong Luoxin Pharmaceutical Group Stock co., ltd
  • 6.14. Takeda Pharmaceutical Co. Ltd.

LIST OF TABLES

  • 1. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL H2-RECEPTOR ANTAGONISTS IN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL GASTRIC PROTON PUMP INHIBITORS IN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL OTHER GASTRIC ANTISECRETORY DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 6. GLOBAL GASTRIC ANTISECRETORY DRUG IN DYSPEPSIA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL GASTRIC ANTISECRETORY DRUG IN PEPTIC ULCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL GASTRIC ANTISECRETORY DRUG IN GASTROESOPHAGEAL REFLUX MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL GASTRIC ANTISECRETORY DRUG IN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 11. GLOBAL GASTRIC ANTISECRETORY DRUG FOR HOSPITAL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL GASTRIC ANTISECRETORY DRUG FOR CLINIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBAL GASTRIC ANTISECRETORY DRUG FOR OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. NORTH AMERICAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 16. NORTH AMERICAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 17. NORTH AMERICAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 18. NORTH AMERICAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 19. EUROPEAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 20. EUROPEAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 21. EUROPEAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 22. EUROPEAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 23. ASIA-PACIFIC GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 24. ASIA-PACIFIC GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 25. ASIA-PACIFIC GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 26. ASIA-PACIFIC GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 27. REST OF THE WORLD GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 28. REST OF THE WORLD GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 29. REST OF THE WORLD GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 30. REST OF THE WORLD GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 2. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 3. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET SHARE BY END-USER, 2021 VS 2028 (%)
  • 4. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 5. GLOBAL H2-RECEPTOR ANTAGONISTS IN GASTRIC ANTISECRETORY DRUG MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 6. GLOBAL GASTRIC PROTON PUMP INHIBITORS IN GASTRIC ANTISECRETORY DRUG MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 7. GLOBAL OTHER GASTRIC ANTISECRETORY DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 8. GLOBAL GASTRIC ANTISECRETORY DRUG IN DYSPEPSIA MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 9. GLOBAL GASTRIC ANTISECRETORY DRUG IN PEPTIC ULCER MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 10. GLOBAL GASTRIC ANTISECRETORY DRUG IN GASTROESOPHAGEAL REFLUX MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 11. GLOBAL GASTRIC ANTISECRETORY DRUG IN OTHER APPLICATIONS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 12. GLOBAL GASTRIC ANTISECRETORY DRUG FOR HOSPITAL MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 13. GLOBAL GASTRIC ANTISECRETORY DRUG FOR CLINIC MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 14. GLOBAL GASTRIC ANTISECRETORY DRUG FOR OTHER END-USERS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 15. US GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. CANADA GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. UK GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. FRANCE GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. GERMANY GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. ITALY GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. SPAIN GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. REST OF EUROPE GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. INDIA GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. CHINA GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. JAPAN GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. SOUTH KOREA GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. REST OF THE WORLD GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)